#PhaseI #SBIR: C5BDI connects the Defense Health Agency #DHA with a #minorityowned #SB based in Irvine, CA, delivering a rapid way to detect invisible #pathogens. This microfluidics platform, developed for rapid detection and quantification of bacteria and other cells, allows users to rapidly test for the presence of certain cells, separate populations of cells based on metabolic or other phenotypic differences, and (if desired) capture them for further analysis. This innovative tech will significantly advance DHA’s ability to achieve test results within minutes vice hours and days in a portable platform that does not require cold chain reagents. From a reliability standpoint, since this technological breakthrough does not require long-term incubation, it is dramatically less susceptible to contamination than conventional tissue culture, dramatically reducing the cost of operation.

Share This